-
Shunxi Holding Group Secures Licensing Deal for Cartherics’ CTH-004 in Greater China
•
China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm Cartherics Pty Ltd, securing the exclusive rights to develop, manufacture, and commercialize Cartherics’ autologous CAR-T cell product, CTH-004, for the treatment of multiple solid tumors, including ovarian cancer, in Greater China. The agreement also grants…
-
AstraZeneca’s MEK Inhibitor Koselugo Approved in China for Pediatric NF1-Related PN
•
UK major AstraZeneca (AZ, NASDAQ: AZN) has announced that its mitogen-activated protein kinase (MEK) inhibitor, Koselugo (selumetinib), has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromatosis (PN) in pediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. This marks a significant advancement in…
-
Shenzhen’s Angio8 Secures Tens of Millions in Series A Financing for Surgical Robot Development
•
Angio8, a Shenzhen-based developer of vascular interventional surgical robots, has reportedly raised tens of millions of renminbi through a Series A financing round. The investment was led by Oriental Fortune Capital, with participation from Kangyu Capital, marking a significant milestone in the company’s growth and development trajectory. Commitment to First-In-Class…
-
BeiGene’s Brukinsa Receives NMPA Approval for Expanded Use in Leukemia and Lymphoma
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it has received approval from China’s National Medical Products Administration (NMPA) for four applications related to Brukinsa (zanubrutinib), the company’s Bruton’s tyrosine kinase inhibitor (BTKi). The approvals include two supplemental New Drug Applications (sNDAs) for the treatment of treatment-naïve…
-
Shanghai Junshi Biosciences’ Tuoyi Shows Promise in Phase III Study for ES-SCLC
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced encouraging results from the Phase III EXTENTORCH study, which assessed the company’s programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) in combination with chemotherapy for first-line extensive stage small cell lung cancer (ES-SCLC). The trial has successfully reached its pre-set primary…
-
Tianjin, Shandong, and Hainan Provinces Announce VBP Backup Suppliers for Round 8
•
Tianjin, Shandong, and Hainan provinces in China have released their lists of backup suppliers following the recently completed Round 8 of the volume-based procurement (VBP) program. For the first time, the backup supplier system has been applied to drugs that are designated as being in dangerously short supply in clinics.…
-
Suzhou GenAssist’s GEN6050 Receives US FDA Pre-IND Acceptance for Duchenne Muscular Dystrophy Treatment
•
China-based Suzhou GenAssist Therapeutic Co., Ltd has announced that the US Food and Drug Administration (FDA) has accepted a pre-Investigational New Drug (pre-IND) application for the company’s first pipeline candidate, GEN6050. This in vivo base editing drug targets exon 50 skipping in the Duchenne muscular dystrophy (DMD) gene, with the…
-
Sinopharm Partners with Fudan University to Establish National Innovation Platform
•
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan University, aimed at leveraging their respective strengths in technology, talent, market, and industry to jointly establish a national innovation platform. This collaboration will focus on the development of new products and technologies, the strengthening of…
